Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina ; volume:8 ; number:5 ; day:13 ; month:7 ; year:2024 ; pages:727-738 ; date:9.2024
PharmacoEconomics - open ; 8, Heft 5 (13.7.2024), 727-738, 9.2024

Creator
Espinola, Natalia
Silvestrini, Constanza
Colaci, Carla
Sugg, Daniela
Rojas-Roque, Carlos
Coelli, Jesica
Augustovski, Federico
Contributor
SpringerLink (Online service)

DOI
10.1007/s41669-024-00508-4
URN
urn:nbn:de:101:1-2411250841230.771878930625
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Espinola, Natalia
  • Silvestrini, Constanza
  • Colaci, Carla
  • Sugg, Daniela
  • Rojas-Roque, Carlos
  • Coelli, Jesica
  • Augustovski, Federico
  • SpringerLink (Online service)

Other Objects (12)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Related objects